BAY AREA CANCER CONNECTIONS
  • Home
  • Events
    • Event Calendar
    • Annual Conference
    • 25th Anniversary Gala
    • Spring Benefit
  • Programs and Services
    • Personalized Support
    • Support Groups
    • Access to Care
    • Personalized Medical Research
    • Boutique
    • Library
  • Community
    • Network
    • Donors
    • Volunteers
    • Partners
  • Donate
    • Fundraising
  • About
    • Story
    • People
    • Financials
    • News
    • Blog
    • Contact Us

BLOG

Immunotherapy for Metastatic Triple-Negative Breast Cancer

5/1/2019

10 Comments

 
Picture
Results from the IMpassion 130 clinical trial show that there is benefit to adding immunotherapy to chemotherapy in the treatment of metastatic triple-negative breast cancer (TNBC). This phase III clinical trial randomized 902 people with untreated metastatic TNBC to treatment with either chemotherapy or chemotherapy plus immunotherapy. The immunotherapy drug used in the study was atezolizumab (Tecentriq), which blocks a protein called PD-L1 that is expressed by some cancer cells. By blocking PD-L1, the drug takes the brakes off the immune system, enabling immune cells (T cells) to attack the tumor. The trial showed that among people with PD-L1-positive tumors, addition of atezolizumab to chemotherapy improved progression free survival (the time before the cancer started growing) and overall survival. Average progression-free survival was 7.5 months in the group treated with chemotherapy plus immunotherapy, versus 5.0 months in the group treated with chemotherapy alone. Average overall survival was 25 months in the combined therapy group versus 15.5 months in the chemotherapy alone group. This study marks the first time that a targeted immunotherapy drug has been shown to improve overall survival in metastatic TNBC. Based on these results, in March 2019 the FDA granted accelerated approval of atezolizumab in combination with chemotherapy for the treatment of metastatic PD-L1-positive triple-negative breast cancer.
(Abstract GS1-04)
Highlights from the 2018 San Antonio Breast Cancer Symposium
By Anh Diep, VMD, PhD Candidate, and Erika Bell, PhD, Manager of Medical Information, Bay Area Cancer Connections
​
In early December 2018, thousands of researchers from across the world convened in San Antonio, Texas, for the 41st Annual San Antonio Breast Cancer Symposium. This five-day symposium brought together experts in basic, translational, and clinical research; clinicians; and patient advocates to present and discuss advances in breast cancer research and treatment. As progress in breast cancer continues, the challenges remain: to personalize treatment based on characteristics of the cancer, to minimize over- and under-treatment, and to maximize quality of life. This article highlights several of the talks from the 2018 symposium that are most likely to have a direct impact on the clinical care of breast cancer patients. For access to complete symposium resources, including abstracts, posters, and presentations, visit sabcs.org.
10 Comments

    Archives

    July 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    October 2018
    August 2018
    May 2018
    March 2018
    February 2018
    January 2018

    Categories

    All

Quick Links

About
​Financials
Ways to Give

Blog

Stay Connected

Never miss an update. Join our email list today! 
SUBSCRIBE NOW!
Picture

Bay Area Cancer Connections
Resource Center
2335 El Camino Real, Palo Alto, California 94306
Email: info@bayareacancer.org
Helpline: 650-326-6686
Business: 650-326-6299 | Toll Free: 888-222-4401 
Fax: 650-326-6673
​​© 2018 Bay Area Cancer Connections. All Rights Reserved.
Terms & Conditions​​ | Privacy Policy
  • Home
  • Events
    • Event Calendar
    • Annual Conference
    • 25th Anniversary Gala
    • Spring Benefit
  • Programs and Services
    • Personalized Support
    • Support Groups
    • Access to Care
    • Personalized Medical Research
    • Boutique
    • Library
  • Community
    • Network
    • Donors
    • Volunteers
    • Partners
  • Donate
    • Fundraising
  • About
    • Story
    • People
    • Financials
    • News
    • Blog
    • Contact Us